First-in-human phase I study of the liposomal RNAi therapeutic Atu027 in patients with advanced cancer.
Beate Schultheis
No relevant relationships to disclose
Dirk Strumberg
No relevant relationships to disclose
Ansgar Santel
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Frank Gebhardt
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Michael Khan
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Oliver Keil
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Klaus Giese
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Jörg Kaufmann
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics